The regulatory window for compounded peptides is reopening. Telehealth companies that can stand up a direct-to-consumer peptide program quickly will capture the wave of patient demand that's been building since the 2024 Category 2 restrictions. But speed without infrastructure is just expensive chaos.
This playbook walks through the operational steps to get from "we want to offer peptides" to "kits are landing on patients' doorsteps" — with emphasis on the supply and fulfillment operations that most new entrants underestimate.
Step 1: Define Your Formulary
Before you touch a single operational decision, lock in what you're actually going to offer. Your formulary drives everything downstream: pharmacy partner selection, kit design, cold chain requirements, patient education content, and pricing.
Start narrow. The temptation is to launch with 10+ peptides. Don't. Start with 2-3 compounds that have high patient demand, established dosing protocols, and straightforward fulfillment requirements.
Recommended launch formulary: BPC-157 (most broadly applicable — tissue repair, gut health, musculoskeletal recovery), CJC-1295/Ipamorelin (standard GH optimization stack), and Thymosin Alpha-1 (immune modulation with international clinical approval and strong provider familiarity).
If you're also offering weight management, semaglutide and/or tirzepatide run on a separate regulatory track but can share kitting infrastructure.
Second wave additions (once operations are stable): AOD-9604, TB-500, Selank/Semax, KPV.
Step 2: Secure Your Pharmacy Partnership
Your 503A pharmacy partner is the single most important vendor relationship in your program.
What to evaluate:
State licensing — active licenses in every state where you have patients. Adding new state licenses takes 4-12 weeks. Verify they can compound your full formulary and ask about API sourcing readiness for reclassified peptides.
Quality systems: USP 795/797 compliance, potency testing, sterility testing, beyond-use dating studies. Ask for their most recent state board inspection report.
Capacity: Can they handle projected volume at 3, 6, and 12 months? Current turnaround time?
Technology: Electronic prescription submission? API or portal? Shipping status communication?
Timeline: Pharmacy partnership evaluation and contracting typically takes 4-8 weeks. Don't shortcut this.
Step 3: Design Your Kit Configurations
The kit is what the patient actually interacts with. It's the physical manifestation of your brand and your clinical program.
Standard injectable peptide kit includes: Medication vial (from pharmacy), syringes matched to protocol (29-31 gauge, 0.5-1mL for most subcutaneous peptides), alcohol swabs, bacteriostatic water for reconstitution (if applicable), sharps container, and patient injection guide with reconstitution instructions, dosing schedule, and storage requirements.
Kit design decisions that matter:
Syringe selection isn't one-size-fits-all. BPC-157 at 250mcg/dose needs a different volume draw than TB-500 at 2.5mg/dose.
Branded vs generic packaging reflects how you want patients to perceive your program. Custom branded kits signal professionalism and build loyalty.
Kit inserts and patient education materials are an underestimated retention tool. A well-designed insert reduces anxiety for first-time injectors and cuts support volume significantly.
Step 4: Build Your Cold Chain Fulfillment
This is where most new telehealth companies hit the wall.
Key decisions:
Do you ship kit and medication together or separately? The combined approach (one box, everything needed) is better for patient experience but requires coordination between pharmacy and fulfillment partner.
Shipping speed and carrier: Overnight or 2-day for cold chain is standard. Ground is viable for lyophilized peptides in moderate weather but risky for anything requiring refrigeration.
Seasonal strategy: You need summer packout protocols — heavier coolants, more insulation, potentially mandatory overnight shipping June-September. Don't wait until July to figure this out.
Build vs buy: Unless you have existing warehouse infrastructure with temperature-controlled storage, outsourcing to a specialized partner is almost always the right call. The capital expenditure, staffing, and learning curve of building in-house delays your launch and diverts focus from patient acquisition.
Step 5: Set Up Your Patient Communication Flow
Minimum communication touchpoints:
- After prescription submission: confirm order is being processed
- When kit ships: send tracking information
- On delivery day: notification to retrieve package quickly (critical for cold chain)
- After delivery: onboarding content — first injection guidance, what to expect
- For recurring programs: refill reminders and shipping notifications
The more automated these handoffs are, the fewer patients fall through the cracks.
Step 6: Compliance and Documentation
Peptide programs operate in a heavily regulated space. Build compliance in from day one.
Federal requirements: Valid prescriber-patient relationships (varies by state), HIPAA compliance for patient data, proper prescription documentation, state-specific telehealth and prescribing regulations.
State pharmacy board requirements: Vary significantly. Some states impose additional restrictions on compounded peptide categories, interstate shipping, or telehealth prescribing of compounded injectables. Build a state-by-state compliance matrix before launching nationally.
Quality documentation: Pharmacy partner CoA documentation, kit component specifications (lot traceability), cold chain packaging validation (ISTA 7E), temperature monitoring records, and patient complaint/adverse event documentation.
Step 7: Launch, Monitor, Iterate
Your first 100 patients are your proof-of-concept. Track these metrics from day one:
- Order-to-delivery time — how long from prescription to kit on doorstep?
- Temperature excursion rate — what percentage of shipments go out of range?
- Patient support ticket volume — are patients confused about reconstitution, injection, storage?
- Kit completeness — are shipments arriving with all components?
- Refill rate — are patients continuing past their initial order?
Common first-90-day problems:
Slow pharmacy turnaround → evaluate capacity vs process issue. Temperature excursions in warm weather → upgrade packaging, switch to overnight, adjust seasonal packout. High support volume around reconstitution → improve patient education, add video content. Low refill rates → diagnose whether it's clinical, operational, or communication.
The Timeline: Realistic Launch Expectations
From decision-to-launch, expect 8-16 weeks for a well-executed buildout:
- Weeks 1-3: Formulary definition, pharmacy partner evaluation, kit design
- Weeks 4-8: Pharmacy contracting, fulfillment partner setup, kit prototyping, patient communication flow
- Weeks 8-12: Test shipments, cold chain validation, compliance review, provider training
- Weeks 12-16: Soft launch with initial patient cohort and monitoring
You can compress this timeline by partnering with a kitting and fulfillment operation that has existing infrastructure, validated packaging, and experience launching peptide programs. Starting from scratch on fulfillment adds months.
The Bottom Line
Launching a DTC peptide program is 20% clinical and 80% operational. The clinical protocols are relatively standardized. The operational infrastructure — pharmacy partnership, kit design, cold chain fulfillment, patient communication, compliance — is where programs succeed or fail.
The telehealth companies that win the post-reclassification market are the ones with this infrastructure locked in before the formal Category 1 restoration is published. The ones that start building after the announcement will be months behind.